Female sex is a risk modifer rather than a risk factor for stroke in atrial fibrillation should we use a CHA 2 DS 2 -VA Score Rather Than CHA 2 DS 2 -VASc?

Circulation

Volumn 137, Issue 8, 2018, Pages 832-840

  Nielsen, Peter Brønnum ^a,b   Skjøth, Flemming ^a,b   Overvad, Thure Filskov ^b   Larsen, Torben Bjerregaard ^a,b   Lip, Gregory Y H ^b,c  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Atrial fbrillation; Risk assessment; Sex characteristics; Stroke; Thromboembolism

Indexed keywords

AGED; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE ASSESSMENT; CEREBROVASCULAR ACCIDENT; CHA2DS2 VA SCORE; CHA2DS2-VASC SCORE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RISK; RISK FACTOR; RISK MODIFIER; SEX DIFFERENCE; THROMBOEMBOLISM; AGE; CLINICAL TRIAL; COMPLICATION; DENMARK; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; REGISTER; SEX FACTOR; SEXUAL CHARACTERISTICS; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; DENMARK; FEMALE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; RISK FACTORS; SEX CHARACTERISTICS; SEX FACTORS; STROKE; THROMBOEMBOLISM;

EID: 85047007912     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.029081     Document Type: Article

References (33)

1. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-1457.
2. Wagstaff AJ, Overvad TF, Lip GY, Lane DA. Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. QJM. 2014;107:955-967. doi: 10.1093/qjmed/hcu054.
3. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB, Larson MG, Kannel WB, Benjamin EJ. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The Framingham Heart Study. JAMA. 2003;290:1049-1056. doi: 10.1001/jama.290.8.1049.
4. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263-272. doi: 10.1378/chest.09-1584.
5. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-2962. doi: 10.1093/eurheartj/ehw210.
6. Overvad TF, Nielsen PB, Lip GY. Treatment thresholds for stroke prevention in atrial fibrillation: Observations on the CHA2DS2-VASc score. Eur Heart J Cardiovasc Pharmacother. 2017;3:37-41. doi: 10.1093/ehjcvp/pvw022.
7. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071-2104. doi: 10.1161/CIR.0000000000000040.
8. Mikkelsen AP, Lindhardsen J, Lip GY, Gislason GH, Torp-Pedersen C, Olesen JB. Female sex as a risk factor for stroke in atrial fibrillation: A nationwide cohort study. J Thromb Haemost. 2012;10:1745-1751. doi: 10.1111/j.1538-7836.2012.04853.x.
9. Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: The Swedish Atrial Fibrillation Cohort study. Eur Heart J. 2015;36:297-306. doi: 10.1093/eurheartj/ehu139.
10. Chan YH, Wu LS, Chang SH, Lee HF, Liu JR, See LC, Yeh YH, Kuo CT. Young male patients with atrial fibrillation and CHA2DS2-VASc score of 1 may not need anticoagulants: A nationwide populationbased study. PLoS One. 2016;11:e0151485. doi: 10.1371/journal. pone.0151485.
11. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen TJ, Lip GY, Chen SA. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol. 2015;65:635-642. doi: 10.1016/j. jacc.2014.11.046.
12. Nielsen PB, Larsen TB, Skjøth F, Overvad TF, Lip GY. Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. Sci Rep. 2016;6:27410. doi: 10.1038/srep27410.
13. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: A review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449-490. doi: 10.2147/CLEP.S91125.
14. Klein JP, Andersen PK. Regression modeling of competing risks data based on pseudovalues of the cumulative incidence function. Biometrics. 2005;61:223-229. doi: 10.1111/j.0006-341X.2005.031209.x.
15. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med. 1999;18:695-706.
16. Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GY. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA. 2015;314:1030-1038. doi: 10.1001/jama.2015.10725.
17. Parner ET, Andersen PK. Regression analysis of censored data using pseudo-observations. Stata J. 2010;10:408-422.
18. Friberg L, Benson L, Rosenqvist M, Lip GY. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: Nationwide retrospective cohort study. BMJ. 2012;344:e3522.
19. Tomita H, Okumura K, Inoue H, Atarashi H, Yamashita T, Origasa H, Tsushima E; J-RHYTHM Registry Investigators. Validation of risk scoring system excluding female sex from CHA2DS2-VASc in Japanese patients with nonvalvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry. Circ J. 2015;79:1719-1726. doi: 10.1253/circj.CJ-15-0095.
20. Nielsen PB, Chao TF. The risks of risk scores for stroke risk assessment in atrial fibrillation. Thromb Haemost. 2015;113:1170-1173. doi: 10.1160/TH15-03-0210.
21. Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand JP, Berge E, Cools F, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Kayani G, Koretsune Y, Mantovani LG, Misselwitz F, Oh S, Turpie AG, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103:307-314. doi: 10.1136/heartjnl-2016-309832.
22. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Bartels DB, Lip GY; GLORIA-AF Investigators. The changing landscape for stroke prevention in AF: Findings from the GLORIA-AF Registry Phase 2. J Am Coll Cardiol. 2017;69:777-785. doi: 10.1016/j.jacc.2016.11.061.
23. Nielsen PB, Larsen TB, Lip GY. Misconceptions on interpretation of risk prediction tools in atrial fibrillation. Am J Med. 2016;129:e31. doi: 10.1016/j.amjmed.2015.11.038.
24. Argulian E, Conen D, Messerli FH. Misconceptions and facts about atrial fibrillation. Am J Med. 2015;128:938-942. doi: 10.1016/j.amjmed. 2015.02.016.
25. Camm AJ, Accetta G, Al Mahmeed W, Ambrosio G, Goldhaber SZ, Haas S, Jansky P, Kayani G, Misselwitz F, Oh S, Oto A, Raatikainen P, Steffel J, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: Contemporary perspective from the GARFIELD-AF registry. BMJ Open. 2017;7:e014579. doi: 10.1136/bmjopen-2016-014579.
26. Guo Y, Wang H, Zhao X, Zhang Y, Zhang D, Ma J, Wang Y, Lip GY. Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. Int J Cardiol. 2013;168:4678-4684. doi: 10.1016/j.ijcard.2013.07.179.
27. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Hormone replacement therapy and adverse outcomes in women with atrial fibrillation: An analysis from the atrial fibrillation follow-up investigation of rhythm management trial. Stroke. 2014;45:3076-3079. doi: 10.1161/STROKEAHA.114.006668.
28. Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: The SAMe-TT?R? score. Chest. 2013;144:1555-1563. doi: 10.1378/chest.13-0054.
29. Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29:541-549. doi: 10.1007/s10654-014-9930-3.
30. Rix TA, Riahi S, Overvad K, Lundbye-Christensen S, Schmidt EB, Joensen AM. Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry. Scand Cardiovasc J. 2012;46:149-153. doi: 10.3109/14017431.2012.673728.
31. Wildenschild C, Mehnert F, Thomsen RW, Iversen HK, Vestergaard K, Ingeman A, Johnsen SP. Registration of acute stroke: Validity in the Danish Stroke Registry and the Danish National Registry of Patients. Clin Epidemiol. 2014;6:27-36. doi: 10.2147/CLEP.S50449.
32. Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. Lancet. 2016;388:806-817. doi: 10.1016/S0140-6736(16)31257-0.
33. Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GY, Mantovani LG, Turpie AG, van Eickels M, Misselwitz F, Rushton-Smith S, Kayani G, Wilkinson P, Verheugt FW; GARFIELD Registry Investigators. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: Perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013;8:e63479. doi: 10.1371/journal.pone.0063479.